Structural Heart Disease
Our structural heart program continues to drive advancements in care for valvular heart conditions.
A national leader in structural heart care
2025 Outcomes
As one of the nation’s most active structural heart programs, we consistently rank among the busiest in the country. By prioritizing next-generation valve technologies and innovations, we have established ourselves as a leader in structural heart care. Through a collaborative, enterprise-wide approach, we deliver comprehensive and personalized care for all four heart valves—aortic, mitral, tricuspid and pulmonary—ensuring optimized patient outcomes and a commitment to clinical excellence.
.
Accomplishments
- Plano was the lead site for the TRISEND II Trial. By performing a transcatheter tricuspid valve replacement using the EVOQUE valve along with medical therapy, we were able to offer this population improved cardiovascular outcomes primarily through improvements in symptoms and quality of life.
- Dallas performed the first Evolut FX+ transcatheter aortic valve replacement (TAVR). Evolut FX+ offers enhanced coronary access in TAVR procedures.
TAVR Volumes
DALLAS, DENTON, FORT WORTH, PLANO
FY 2023
665
FY 2024
688
FY 2025
724
ENTERPRISE AT A GLANCE:
40% GROWTH
In MitraClip cases from 2024 to 2025
27% M-TEER GROWTH
in the last 12-month period
M-TEER: DALLAS, FORT WORTH, PLANO
110
90
70
0
FY23
FY24
FY25
STRUCTURAL HEART OUTCOMES – FY25
| Procedure | Mortality | National Average |
|---|---|---|
| TAVR | 0.7% | 1% |
| M-TEER* | 0% | 1.5% |
| TTVR** | 0% | 1.5% |
Rolling 12 months from March 2024–Feb. 2025
*Dallas, Plano and Fort Worth **Dallas and Plano
Innovations
- Our structural heart team has expertise in lifetime management of aortic valve disease. They determine whether a patient needs TAVR or surgical aortic valve replacement (SAVR), allowing for a personalized approach to ensure the optimal treatment plan and outcomes. The surgical program in Plano has had a 0% mortality rate for SAVR for the past two years and maintains special expertise in TAVR explant.
- Our team continues to push the limits with early feasibility studies, participating in Twist2 and CardioMech. Our teams also participate in trials evaluating the safety and performance of valve replacement systems, such as the Innovalve mitral valve replacement system for patients with moderate-to-severe mitral regurgitation and the JenaValve J-Valve TF System for patients with severe aortic regurgitation at high risk for surgery.
- Dallas and Plano persistently advance boundaries in transcatheter edge-to-edge repair. Plano was the first site in the country to perform an EVOQUE transcatheter tricuspid valve replacement during the early feasibility study. This FDA-approved device can be used for both repair and replacement and has been strongly shown to improve quality of life for patients.
Quality awards 2025
Achievements placing us among the elite
Heart & Vascular Surgery
Denton: 3 Stars in 2 Categories
Denton
Previous
Next